Skip to main content

Table 1 Characteristics of the included patients

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Variable anti-HBc positive, n (%) anti-HBc negative, n (%) P value High-titer anti-HBc, n (%) Low-titer anti-HBc, n (%) P value
N 125 202   39 86  
Age (years) 61.32 ± 8.01 60.61 ± 7.55 0.419 59.44 ± 7.469 62.17 ± 8.147 0.077
Gender    0.027*    0.154
 Male 85 (68) 112 (55.4)   23 (59.0) 62 (72.1)  
 Female 40 (32) 90 (44.6)   16 (41.0) 24 (27.9)  
Tumor site   0.72    1
 Colon 44 (35.2) 67 (33.2)   14 (35.9) 30 (34.9)  
 Rectum 81 (64.8) 135 (66.8)   25 (64.1) 56 (65.1)  
T stage    0.458    0.523
 T1 1 (0.8) 1 (0.5)   0 (0) 1 (1.2)  
 T2 4 (3.2) 9 (4.5)   0 (0) 4 (4.7)  
 T3 120 (96) 188 (93.1)   39 (100) 81 (94.2)  
 T4 0 (0) 4 (2)   0 (0) 0 (0)  
N stage    0.288    0.202
 N0 65 (52) 121 (59.9)   20 (51.3) 45 (52.3)  
 N1 41 (32.8) 60 (29.7)   10 (25.6) 31 (36)  
 N2 19 (15.2) 21 (10.4)   9 (23.1) 10 (11.6)  
TNM stage   0.167    1
 II 65 (52) 122 (60.4)   20 (51.3) 45 (52.3)  
 III 60 (48) 80 (39.6)   19 (48.7) 41 (47.7)  
Histological types   0.447    0.092
 Adenocarcinoma 107 (85.6) 166 (82.2)   31 (79.5) 78 (90.7)  
 Mucinous adenocarcinoma 18 (14.4) 36 (17.8)   8 (20.5) 8 (9.3)  
Differentiation   0.652    0.253
 Well 6 (4.8) 10 (5)   1 (2.6) 5 (5.8)  
 Moderately 87 (69.6) 152 (75.2)   29 (74.4) 58 (67.4)  
 Poorly 19 (15.2) 22 (10.9)   3 (7.7) 16 (18.6)  
 Not Available 13 (10.4) 18 (8.9)   6 (15.4) 7 (8.1)  
Neoadjuvant therapy 1    0.501
 Yes 10 (8) 15 (7.4)   4 (10.3) 6 (7)  
 No 115 (92) 187 (92.6)   35 (89.7) 80 (93)  
Retrieved LN   0.173    0.663
 < 12 32 (25.6) 67 (33.2)   11 (28.2) 21 (24.4)  
  ≥ 12 93 (74.4) 135 (66.8)   28 (71.8) 65 (75.6)  
CEA (ng/ml)   0.909    0.332
  ≤ 5 70 (56) 111 (55)   19 (48.7) 51 (59.3)  
 > 5 55 (44) 91 (45)   20 (51.3) 35 (40.7)  
CA19-9(U/ml)   0.492    0.27
  ≤ 37 107 (85.6) 179 (88.6)   31 (79.5) 76 (88.4)  
 > 37 18 (14.4) 23 (11.4)   8 (20.5) 10 (11.6)  
ALT(U/L) 17.65 ± 9.50 19.86 ± 15.86 0.377 18.41 ± 9.85 17.31 ± 9.37 0.434
AST(U/L) 18.42 ± 6.70 19.01 ± 9.60 0.892 18.10 ± 6.12 18.56 ± 6.98 0.94
ALP(U/L) 83.90 ± 21.67 84.66 ± 24.98 0.86 82.56 ± 20.30 84.51 ± 22.34 0.643
PLT (1 × 109/L) 252.90 ± 67.98 250.91 ± 77.43 0.622 261.97 ± 67.56 84.51 ± 22.34 0.317
  1. Abbreviations: anti-HBc, antibodies to hepatitis B core antigen, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase; PLT, platelets; LN, lymph node
  2. *Significant at P < 0.05